Renal function after acyclovir intravenous injection

https://doi.org/10.1016/0002-9343(82)90087-0Get rights and content

Abstract

Plasma urea or creatinine was noted to be raised in 58 of 354 patients treated with intravenous acyclovir. This occurred after intravenous bolus injection of high dosages of acyclovir but the risk was considerably reduced by slow intravenous infusion of the same dosage over one hour, with adequate hydration of the patient and adjustment of dosage in patients with preexisting impaired renal function. Animal studies indicate that the impairment of renal function associated with high bolus injections of acyclovir is due to crystal formation in the renal tubules and/or the collecting ducts, and that the crystals are removed after cessation of treatment. The special problems involved in the treatment of patients with herpes encephalitis necessitating limited fluid intake and the possible interaction with other nephrotoxic drugs are discussed.

References (3)

There are more references available in the full text version of this article.

Cited by (139)

  • Novel Insights to Enhance Therapeutics With Acyclovir in the Management of Herpes Simplex Encephalitis

    2021, Journal of Pharmaceutical Sciences
    Citation Excerpt :

    Acyclovir crystalluria has also been reported in urinary sediment (needle-like crystals) of patients receiving IV acyclovir infusion at the dosage of 500 mg/m2 8-hourly as a 1-h infusion.78 Minimal histologic changes are seen in these trials and the changes are completely reversible on cessation of treatment.80 Dose adjustment is necessary when IV acyclovir is given to patients with end-stage renal disease to avoid drug accumulation, which is based on creatinine clearance.26,74,75

  • Acute kidney injury (AKI) associated with intravenous aciclovir in adults: Incidence and risk factors in clinical practice

    2018, International Journal of Infectious Diseases
    Citation Excerpt :

    A binomial logistic regression model (Χ2 = 19.2, P < 0.001) indicated that daily dose (OR 2.4 per gram [95% CI: 1.3–4.5] P = 0.005) and CKD (OR 9.5 [95% CI: 2.3–39.3] P = 0.002) were independent risk factors. The rate of aciclovir-associated AKI reported here is consistent with previous reports (Brigden et al., 1982; Sawyer et al., 1988; Rao et al., 2015; Pierson-Marchandise et al., 2017) indicating that in contemporary clinical practice, aciclovir is comparable to other more widely-perceived nephrotoxic antimicrobials such as gentamicin (Paquette et al., 2015) or vancomycin (van Hal et al., 2013). Unlike other antivirals, aciclovir does not compete with creatinine for tubular excretion (Gunness et al., 2010), therefore the elevations in serum creatinine we observe are a true reflection of renal damage.

  • Acyclovir-induced nephrotoxicity in a pregnant woman with chickenpox

    2016, Taiwanese Journal of Obstetrics and Gynecology
  • Acyclovir induced hypokalemia

    2013, Journal of Clinical Virology
  • Acyclovir-Induced Nephrotoxicity in Adults with Viral Encephalitis

    2024, Journal of the College of Physicians and Surgeons Pakistan
View all citing articles on Scopus
1

From the Wellcome Research Laboratories, Beckenham, Kent, England.

View full text